Page 12 - Trials Network News Today

-- Expert in virology, immunology and vaccine development’s appointment effective August 12 --...

One trial confirmed the efficacy of CAB LA for transgender women who were also receiving gender-affirming hormone therapy.

Interfaith America

DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084...

Scientists, doctors and other health professionals from the HIV Vaccine Trials Network (HVTN) will present research findings and other HIV-related news at AIDS

Advances in long-acting treatment and prevention for HIV are changing the way we treat our patients.

"Given the high vulnerability to HIV acquisition for the adolescent population, and the evidence linking gender norms to HIV acquisition and current and future programming designed to modify norms, it is important to understand the measurement properties of the GEMS instrument for this population."

For media and investors only Issued: London UK Primary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against symptomatic... | June 24, 2022

Primary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against symptomatic infection in adults, and 75.1% efficacy in participants previously infected with COVID-19 Against Omicron, sequencing analysis performed to date shows 72% efficacy in all adults and 93.2% in seropositives Favorable safety and tolerability profile

Two scientists associated with Stellenbosch University (SU) have been selected for this year’s TIME 100 Most Influential People list.